{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:53:57Z","timestamp":1761238437749,"version":"3.40.5"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["9R01NS090904-16","RO1HL052246","PO1 HL031950"],"award-info":[{"award-number":["9R01NS090904-16","RO1HL052246","PO1 HL031950"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fondation Leducq Transatlantic Network of Excellence","award":["16 CVD 05"],"award-info":[{"award-number":["16 CVD 05"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.neuropharm.2017.09.021","type":"journal-article","created":{"date-parts":[[2017,9,18]],"date-time":"2017-09-18T21:48:58Z","timestamp":1505771338000},"page":"293-301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"PB","title":["Can adjunctive therapies augment the efficacy of endovascular thrombolysis? A potential role for activated protein C"],"prefix":"10.1016","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9122-3338","authenticated-orcid":false,"given":"Arun Paul","family":"Amar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhay P.","family":"Sagare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaoming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy R.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John H.","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berislav V.","family":"Zlokovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2017.09.021_bib1","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3174\/ajnr.A3707","article-title":"Complications of endovascular treatment for acute stroke in the SWIFT trial with solitaire and Merci devices","volume":"35","author":"Akins","year":"2014","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib2","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1161\/STROKEAHA.111.618850","article-title":"Stroke Treatment Academic Industry Roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies","volume":"42","author":"Albers","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.neuropharm.2017.09.021_bib3","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.3174\/ajnr.A3855","article-title":"Impact of age and baseline NIHSS scores on clinical outcomes in the mechanical thrombectomy using solitaire FR in acute ischemic stroke study","volume":"35","author":"Almekhlafi","year":"2014","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib4","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3389\/fncel.2015.00344","article-title":"Combined neurothrombectomy or thrombolysis with adjunctive delivery of 3K3A-activated protein C in acute ischemic stroke","volume":"9","author":"Amar","year":"2015","journal-title":"Front. Cell Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/ijs.12434","article-title":"Revisiting cerebral postischemic reperfusion injury: new insights in understanding reperfusion failure, hemorrhage, and edema","volume":"10","author":"Bai","year":"2015","journal-title":"Int. J. Stroke"},{"key":"10.1016\/j.neuropharm.2017.09.021_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411587","article-title":"A\u00a0randomized trial of intraarterial treatment for acute ischemic stroke","volume":"372","author":"Berkhemer","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/cc2167","article-title":"Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis","volume":"7","author":"Bernard","year":"2003","journal-title":"Crit. Care"},{"key":"10.1016\/j.neuropharm.2017.09.021_bib8","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/ACO.0000000000000482","article-title":"Neurotoxicity of anesthetic drugs: an update","volume":"30","author":"Bilotta","year":"2017","journal-title":"Curr. Opin. Anaesthesiol."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib9","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/01.STR.0000247888.25985.62","article-title":"Cell transplantation therapy for stroke","volume":"38","author":"Bliss","year":"2007","journal-title":"Stroke"},{"key":"10.1016\/j.neuropharm.2017.09.021_bib10","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJMoa1414792","article-title":"Endovascular therapy for ischemic stroke with perfusion-imaging selection","volume":"372","author":"Campbell","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib11","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nm826","article-title":"Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective","volume":"9","author":"Cheng","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib12","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1038\/nm1498","article-title":"Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage","volume":"12","author":"Cheng","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib13","doi-asserted-by":"crossref","first-page":"L455","DOI":"10.1152\/ajplung.00093.2013","article-title":"Protein C and acute inflammation: a clinical and biological perspective","volume":"305","author":"Christiaans","year":"2013","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/jcbfm.2008.117","article-title":"Endothelial protein C receptor-assisted transport of activated protein C across the mouse blood-brain barrier","volume":"29","author":"Deane","year":"2009","journal-title":"J.\u00a0Cereb. Blood Flow. Metab."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib15","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nm0298-148","article-title":"tPA: a neuron buster, too?","volume":"4","author":"del Zoppo","year":"1998","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib16","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1182\/blood-2002-12-3680","article-title":"Activated protein C alters cytosolic calcium flux in human brain endothelium via binding to endothelial protein C receptor and activation of protease activated receptor-1","volume":"101","author":"Domotor","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.neuropharm.2017.09.021_bib17","doi-asserted-by":"crossref","first-page":"26S","DOI":"10.1378\/chest.124.3_suppl.26S","article-title":"The protein C pathway","volume":"124","author":"Esmon","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.neuropharm.2017.09.021_bib18","doi-asserted-by":"crossref","first-page":"10564","DOI":"10.1074\/jbc.M116.770040","article-title":"Thrombin activation of protein C requires prior processing by a liver proprotein convertase","volume":"292","author":"Essalmani","year":"2017","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib19","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1079-9796(03)00034-2","article-title":"Recombinant murine-activated protein C is neuroprotective in a murine ischemic stroke model","volume":"30","author":"Fernandez","year":"2003","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib20","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1038\/cddis.2009.22","article-title":"Human embryonic stem cell neural differentiation and enhanced cell survival promoted by hypoxic preconditioning","volume":"1","author":"Francis","year":"2010","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib21","doi-asserted-by":"crossref","first-page":"26486","DOI":"10.1016\/S0021-9258(18)47220-1","article-title":"Identification, cloning, and regulation of a novel endothelial cell protein C\/activated protein C receptor","volume":"269","author":"Fukudome","year":"1994","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib22","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.neuron.2015.05.041","article-title":"Novel stroke therapeutics: unraveling stroke pathophysiology and its impact on clinical treatments","volume":"87","author":"George","year":"2015","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2017.09.021_bib23","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1161\/STROKEAHA.108.528877","article-title":"Current status of neuroprotection for cerebral ischemia: synoptic overview","volume":"40","author":"Ginsberg","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.neuropharm.2017.09.021_bib24","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/j.1471-4159.2009.06380.x","article-title":"Endothelial protein C receptor is expressed in rat cortical and hippocampal neurons and is necessary for protective effect of activated protein C at glutamate excitotoxicity","volume":"111","author":"Gorbacheva","year":"2009","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib25","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.neuroscience.2009.11.027","article-title":"Activated protein C prevents glutamate- and thrombin-induced activation of nuclear factor-kappaB in cultured hippocampal neurons","volume":"165","author":"Gorbacheva","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2017.09.021_bib26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.neuint.2013.05.008","article-title":"NF-kappaB-dependent and -independent pathways in the protective effects of activated protein C in hippocampal and cortical neurons at excitotoxicity","volume":"63","author":"Gorbacheva","year":"2013","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib27","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1134\/S0006297908060138","article-title":"Activated protein C via PAR1 receptor regulates survival of neurons under conditions of glutamate excitotoxicity","volume":"73","author":"Gorbacheva","year":"2008","journal-title":"Biochem. (Mosc)"},{"key":"10.1016\/j.neuropharm.2017.09.021_bib28","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1160\/TH07-03-0228","article-title":"Protease-activated receptor (PAR)1-mediated anti-apoptotic effect of activated protein C on glutamate excitotoxicity in hippocampal neurons","volume":"98","author":"Gorbacheva","year":"2007","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib29","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1414905","article-title":"Randomized assessment of rapid endovascular treatment of ischemic stroke","volume":"372","author":"Goyal","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib30","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood.V82.7.1989.1989","article-title":"Anticoagulant protein C pathway defective in majority of thrombophilic patients","volume":"82","author":"Griffin","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.neuropharm.2017.09.021_bib31","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1172\/JCI110385","article-title":"Deficiency of protein C in congenital thrombotic disease","volume":"68","author":"Griffin","year":"1981","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib32","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bcmd.2005.12.023","article-title":"The promise of protein C","volume":"36","author":"Griffin","year":"2006","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib33","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1161\/ATVBAHA.116.308038","article-title":"2016 Scientific sessions sol sherry distinguished lecturer in thrombosis: thrombotic stroke: neuroprotective therapy by recombinant-activated protein C","volume":"36","author":"Griffin","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib34","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1053\/shem.2002.34093","article-title":"Activated protein C: potential therapy for severe sepsis, thrombosis, and stroke","volume":"39","author":"Griffin","year":"2002","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib35","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1182\/blood-2015-02-355974","article-title":"Activated protein C: biased for translation","volume":"125","author":"Griffin","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.neuropharm.2017.09.021_bib36","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1182\/blood.V79.9.2340.2340","article-title":"Direct detection of activated protein C in blood from human subjects","volume":"79","author":"Gruber","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.neuropharm.2017.09.021_bib37","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0896-6273(04)00019-4","article-title":"Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3","volume":"41","author":"Guo","year":"2004","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2017.09.021_bib38","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/j.1460-9568.2009.06664.x","article-title":"Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity","volume":"29","author":"Guo","year":"2009","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib39","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1471-4159.2009.05921.x","article-title":"Species-dependent neuroprotection by activated protein C mutants with reduced anticoagulant activity","volume":"109","author":"Guo","year":"2009","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib40","doi-asserted-by":"crossref","first-page":"6181","DOI":"10.1523\/JNEUROSCI.4491-12.2013","article-title":"An activated protein C analog stimulates neuronal production by human neural progenitor cells via a PAR1-PAR3-S1PR1-Akt pathway","volume":"33","author":"Guo","year":"2013","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib41","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/STR.0b013e318284056a","article-title":"Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"44","author":"Jauch","year":"2013","journal-title":"Stroke"},{"key":"10.1016\/j.neuropharm.2017.09.021_bib42","doi-asserted-by":"crossref","first-page":"63","DOI":"10.15283\/ijsc.2014.7.2.63","article-title":"Efficacy and safety of stem cell therapies for patients with stroke: a systematic review and single arm meta-analysis","volume":"7","author":"Jeong","year":"2014","journal-title":"Int. J. Stem Cells"},{"key":"10.1016\/j.neuropharm.2017.09.021_bib43","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0140-6736(16)30513-X","article-title":"Human neural stem cells in patients with chronic ischaemic stroke (PISCES): a phase 1, first-in-man study","volume":"388","author":"Kalladka","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2017.09.021_bib44","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/ced.12361","article-title":"Use of dermal injection of activated protein C for treatment of large chronic wounds secondary to pyoderma gangrenosum","volume":"39","author":"Kapila","year":"2014","journal-title":"Clin. Exp. Dermatol"},{"key":"10.1016\/j.neuropharm.2017.09.021_bib45","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1172\/JCI24030","article-title":"Mice with a severe deficiency in protein C display prothrombotic and proinflammatory phenotypes and compromised maternal reproductive capabilities","volume":"115","author":"Lay","year":"2005","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib46","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/j.1747-4949.2012.00797.x","article-title":"Stem cell-based therapy for experimental stroke: a systematic review and meta-analysis","volume":"7","author":"Lees","year":"2012","journal-title":"Int. J. Stroke"},{"key":"10.1016\/j.neuropharm.2017.09.021_bib47","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/WCO.0000000000000023","article-title":"Stem cell therapy for acute cerebral injury: what do we know and what will the future bring?","volume":"26","author":"Lemmens","year":"2013","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib48","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/nm1122","article-title":"Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C","volume":"10","author":"Liu","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib49","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.pneurobio.2013.11.007","article-title":"Cell based therapies for ischemic stroke: from basic science to bedside","volume":"115","author":"Liu","year":"2014","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib50","doi-asserted-by":"crossref","first-page":"7479","DOI":"10.2174\/1381612819666131230131454","article-title":"Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteers","volume":"19","author":"Lyden","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib51","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1161\/STROKEAHA.116.013881","article-title":"Selecting patients for intra-arterial therapy in the context of a clinical trial for neuroprotection","volume":"47","author":"Lyden","year":"2016","journal-title":"Stroke"},{"key":"10.1016\/j.neuropharm.2017.09.021_bib52","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood.V59.5.1067.1067","article-title":"Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme","volume":"59","author":"Marlar","year":"1982","journal-title":"Blood"},{"key":"10.1016\/j.neuropharm.2017.09.021_bib53","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0022-3476(89)80688-2","article-title":"Diagnosis and treatment of homozygous protein C deficiency. Report of the working party on homozygous protein C deficiency of the subcommittee on protein C and protein S, international committee on thrombosis and haemostasis","volume":"114","author":"Marlar","year":"1989","journal-title":"J.\u00a0Pediatr."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib54","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","article-title":"Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"385","author":"Mortality","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2017.09.021_bib55","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.2741\/1977","article-title":"Protein C anticoagulant activity in relation to anti-inflammatory and anti-apoptotic activities","volume":"11","author":"Mosnier","year":"2006","journal-title":"Front. Biosci."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib56","doi-asserted-by":"crossref","first-page":"5237","DOI":"10.1182\/blood-2012-08-452169","article-title":"Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46","volume":"120","author":"Mosnier","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.neuropharm.2017.09.021_bib57","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1182\/blood-2006-09-003004","article-title":"The cytoprotective protein C pathway","volume":"109","author":"Mosnier","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.neuropharm.2017.09.021_bib58","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1161\/CIR.0000000000000152","article-title":"Heart disease and stroke statistics\u20132015 update: a report from the American Heart Association","volume":"131","author":"Mozaffarian","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.neuropharm.2017.09.021_bib59","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(12)61299-9","article-title":"Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial","volume":"380","author":"Nogueira","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2017.09.021_bib60","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1227\/01.NEU.0000363148.49779.68","article-title":"Activated protein C is neuroprotective and mediates new blood vessel formation and neurogenesis after controlled cortical impact","volume":"66","author":"Petraglia","year":"2010","journal-title":"Neurosurgery"},{"key":"10.1016\/j.neuropharm.2017.09.021_bib61","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3389\/fncel.2014.00347","article-title":"Stem cell therapies in preclinical models of stroke associated with aging","volume":"8","author":"Popa-Wagner","year":"2014","journal-title":"Front. Cell Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib62","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1161\/01.STR.0000258112.14918.24","article-title":"The impact of recanalization on ischemic stroke outcome: a meta-analysis","volume":"38","author":"Rha","year":"2007","journal-title":"Stroke"},{"key":"10.1016\/j.neuropharm.2017.09.021_bib63","doi-asserted-by":"crossref","first-page":"6393","DOI":"10.1073\/pnas.0810687106","article-title":"Caveolae are required for protease-selective signaling by protease-activated receptor-1","volume":"106","author":"Russo","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib64","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1161\/01.STR.0000196957.55928.ab","article-title":"Time is brain\u2013quantified","volume":"37","author":"Saver","year":"2006","journal-title":"Stroke"},{"key":"10.1016\/j.neuropharm.2017.09.021_bib65","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1056\/NEJMoa1415061","article-title":"Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke","volume":"375","author":"Saver","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib66","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S0140-6736(12)61384-1","article-title":"Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial","volume":"380","author":"Saver","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2017.09.021_bib67","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1161\/CIRCOUTCOMES.111.000095","article-title":"Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at Get With The Guidelines-Stroke hospitals","volume":"6","author":"Schwamm","year":"2013","journal-title":"Circ. Cardiovasc Qual. Outcomes"},{"key":"10.1016\/j.neuropharm.2017.09.021_bib68","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1161\/01.CIR.103.13.1799","article-title":"Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke","volume":"103","author":"Shibata","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.neuropharm.2017.09.021_bib69","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3390\/brainsci3010239","article-title":"Stem cell transplantation for neuroprotection in stroke","volume":"3","author":"Shinozuka","year":"2013","journal-title":"Brain Sci."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib70","doi-asserted-by":"crossref","first-page":"E1372","DOI":"10.1073\/pnas.1112482108","article-title":"Activated protein C promotes protease-activated receptor-1 cytoprotective signaling through beta-arrestin and dishevelled-2 scaffolds","volume":"108","author":"Soh","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib71","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1161\/STROKEAHA.108.526863","article-title":"Stem Cell Therapies as an Emerging Paradigm in Stroke (STEPS): bridging basic and clinical science for cellular and neurogenic factor therapy in treating stroke","volume":"40","author":"Stem Cell Therapies as an Emerging Paradigm in Stroke, P","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.neuropharm.2017.09.021_bib72","doi-asserted-by":"crossref","first-page":"12788","DOI":"10.1523\/JNEUROSCI.3485-08.2008","article-title":"Activated protein C promotes neovascularization and neurogenesis in postischemic brain via protease-activated receptor 1","volume":"28","author":"Thiyagarajan","year":"2008","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib73","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1161\/STROKEAHA.113.000731","article-title":"Novel approaches to neuroprotection trials in acute ischemic stroke","volume":"44","author":"Tymianski","year":"2013","journal-title":"Stroke"},{"key":"10.1016\/j.neuropharm.2017.09.021_bib74","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.brainres.2010.05.075","article-title":"Activated protein C analog with reduced anticoagulant activity improves functional recovery and reduces bleeding risk following controlled cortical impact","volume":"1347","author":"Walker","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib75","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.bcmd.2013.02.009","article-title":"Neurotoxicity of the anticoagulant-selective E149A-activated protein C variant after focal ischemic stroke in mice","volume":"51","author":"Wang","year":"2013","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib76","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1161\/STROKEAHA.113.003350","article-title":"Activated protein C analog protects from ischemic stroke and extends the therapeutic window of tissue-type plasminogen activator in aged female mice and hypertensive rats","volume":"44","author":"Wang","year":"2013","journal-title":"Stroke"},{"key":"10.1016\/j.neuropharm.2017.09.021_bib77","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/nm.4154","article-title":"3K3A-activated protein C stimulates postischemic neuronal repair by human neural stem cells in mice","volume":"22","author":"Wang","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib78","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/iwj.12125","article-title":"Treatment of chronic diabetic lower leg ulcers with activated protein C: a randomised placebo-controlled, double-blind pilot clinical trial","volume":"12","author":"Whitmont","year":"2015","journal-title":"Int. Wound J."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib79","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/iwj.12343","article-title":"Activated protein C to heal pressure ulcers","volume":"13","author":"Wijewardena","year":"2016","journal-title":"Int. Wound J."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib80","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1177\/1534734611417342","article-title":"Combination of activated protein C and topical negative pressure rapidly regenerates granulation tissue over exposed bone to heal recalcitrant orthopedic wounds","volume":"10","author":"Wijewardena","year":"2011","journal-title":"Int. J. Low. Extrem Wounds"},{"key":"10.1016\/j.neuropharm.2017.09.021_bib81","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.2174\/138161212802430413","article-title":"Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for ischemic stroke","volume":"18","author":"Williams","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib82","doi-asserted-by":"crossref","first-page":"E1035","DOI":"10.1073\/pnas.1401595111","article-title":"Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice","volume":"111","author":"Winkler","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib83","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13287-015-0167-1","article-title":"The immune response of stem cells in subretinal transplantation","volume":"6","author":"Xian","year":"2015","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib84","first-page":"3437","article-title":"Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells","volume":"119","author":"Zhong","year":"2009","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib85","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.tins.2011.01.005","article-title":"Cytoprotective protein C pathways and implications for stroke and neurological disorders","volume":"34","author":"Zlokovic","year":"2011","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2017.09.021_bib86","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/ana.20602","article-title":"Functional recovery after embolic stroke in rodents by activated protein C","volume":"58","author":"Zlokovic","year":"2005","journal-title":"Ann. Neurol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817304380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817304380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T00:02:51Z","timestamp":1659484971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390817304380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":86,"alternative-id":["S0028390817304380"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.09.021","relation":{},"ISSN":["0028-3908"],"issn-type":[{"type":"print","value":"0028-3908"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can adjunctive therapies augment the efficacy of endovascular thrombolysis? A potential role for activated protein C","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.09.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}